VEGFA and acute myeloid leukemia: Following preclinical confirmation of decreased proliferation of AML blasts ex vivo (Karp et al., 2004; Zahiragic et al., 2007), early trials as monotherapy in AML demonstrated capacity to reduce VEGF expression within BM, but without impacting blast burden or outcome (Zahiragic et al., 2007).